Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 7/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30461710 | 1.00 | DYRK1A (0.40) | DYRK1AKCNH2GSK3BPIK3C3PRKD1 | |
| SCHEMBL25421481 | 0.88 | DYRK1A (0.41) | DYRK1AKCNH2GSK3BPIK3C3PDPK1 | |
| SCHEMBL30461674 | 0.88 | DYRK1A (0.41) | DYRK1AKCNH2GSK3BPIK3C3PDPK1 | |
| SCHEMBL30461615 | 0.88 | DYRK1A (0.53) | DYRK1AKCNH2GSK3BPIK3C3 | |
| SCHEMBL25420888 | 0.88 | DYRK1A (0.53) | DYRK1AKCNH2GSK3BPIK3C3 | |
| SCHEMBL30461629 | 0.83 | GPR119 (0.43) | DYRK1AKCNH2GSK3BPIK3C3CYP2C9 | |
| SCHEMBL25420515 | 0.83 | DYRK1A (0.50) | DYRK1AKCNH2GSK3BPRKD1 | |
| SCHEMBL30461665 | 0.83 | DYRK1A (0.50) | DYRK1AKCNH2GSK3BPRKD1 | |
| SCHEMBL25421304 | 0.77 | PIK3C3 (0.57) | DYRK1AKCNH2GSK3BPIK3C3PDPK1 | |
| SCHEMBL25423592 | 0.76 | DYRK1A (0.58) | DYRK1AKCNH2GSK3BPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444721-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107722-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |